Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Source :: Business Wire. December 3, 2020
Publication Year :: 2020
Abstract: Expanded Access Program Established for Patients in the U.S. Who May Benefit from Investigational Therapy While Application is Under Review RARITAN, N.J. -- The Janssen Pharmaceutical Companies of Johnson & [...]

Subjects :: United States. Food and Drug Administration
Johnson & Johnson
Osimertinib
Chemotherapy
Small cell lung cancer -- Genetic aspects -- Drug therapy
Epidermal growth factors -- Genetic aspects
Pharmaceutical industry
Drug approval
Non-small cell lung cancer -- Genetic aspects -- Drug therapy
Cancer metastasis -- Genetic aspects -- Drug therapy
Business
Business, international

Tools